UGT1A1 and neutropenia: UGT1A1 activity is reduced in the UGT1A1 *28/*28 phenotype, which is found in approximately 10% of North American patients; this polymorphism leads to a higher risk of neutropenia and diarrhea with irinotecan therapy27–29.